vs
渤健（BIIB）与Expeditors International（EXPD）财务数据对比。点击上方公司名可切换其他公司
Expeditors International的季度营收约是渤健的1.3倍（$2.9B vs $2.3B），Expeditors International净利率更高（7.0% vs -2.1%，领先9.2%），Expeditors International同比增速更快（-3.3% vs -7.1%），渤健自由现金流更多（$468.0M vs $270.3M），过去两年Expeditors International的营收复合增速更高（13.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
美国财富500强物流服务企业，总部位于华盛顿州贝尔维尤，依托覆盖六大洲100余个国家超340个网点的全球网络及统一集成的技术系统，为客户提供高度优化的定制化供应链解决方案。
BIIB vs EXPD — 直观对比
营收规模更大
EXPD
是对方的1.3倍
$2.3B
营收增速更快
EXPD
高出3.8%
-7.1%
净利率更高
EXPD
高出9.2%
-2.1%
自由现金流更多
BIIB
多$197.7M
$270.3M
两年增速更快
EXPD
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.9B |
| 净利润 | $-48.9M | $200.7M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 8.8% |
| 净利率 | -2.1% | 7.0% |
| 营收同比 | -7.1% | -3.3% |
| 净利润同比 | -118.3% | -14.9% |
| 每股收益（稀释后） | $-0.35 | $1.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBEXPD
| Q4 25 | $2.3B | $2.9B | ||
| Q3 25 | $2.5B | $2.9B | ||
| Q2 25 | $2.6B | $2.7B | ||
| Q1 25 | $2.4B | $2.7B | ||
| Q4 24 | $2.5B | $3.0B | ||
| Q3 24 | $2.5B | $3.0B | ||
| Q2 24 | $2.5B | $2.4B | ||
| Q1 24 | $2.3B | $2.2B |
净利润BIIBEXPD
| Q4 25 | $-48.9M | $200.7M | ||
| Q3 25 | $466.5M | $222.3M | ||
| Q2 25 | $634.8M | $183.6M | ||
| Q1 25 | $240.5M | $203.8M | ||
| Q4 24 | $266.7M | $235.9M | ||
| Q3 24 | $388.5M | $229.6M | ||
| Q2 24 | $583.6M | $175.5M | ||
| Q1 24 | $393.4M | $169.2M |
毛利率BIIBEXPD
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBEXPD
| Q4 25 | -2.5% | 8.8% | ||
| Q3 25 | 22.0% | 10.0% | ||
| Q2 25 | 28.1% | 9.3% | ||
| Q1 25 | 12.8% | 10.0% | ||
| Q4 24 | 11.9% | 10.2% | ||
| Q3 24 | 18.3% | 10.1% | ||
| Q2 24 | 28.3% | 9.2% | ||
| Q1 24 | 20.3% | 9.7% |
净利率BIIBEXPD
| Q4 25 | -2.1% | 7.0% | ||
| Q3 25 | 18.4% | 7.7% | ||
| Q2 25 | 24.0% | 6.9% | ||
| Q1 25 | 9.9% | 7.6% | ||
| Q4 24 | 10.9% | 8.0% | ||
| Q3 24 | 15.8% | 7.7% | ||
| Q2 24 | 23.7% | 7.2% | ||
| Q1 24 | 17.2% | 7.7% |
每股收益（稀释后）BIIBEXPD
| Q4 25 | $-0.35 | $1.50 | ||
| Q3 25 | $3.17 | $1.64 | ||
| Q2 25 | $4.33 | $1.34 | ||
| Q1 25 | $1.64 | $1.47 | ||
| Q4 24 | $1.82 | $1.68 | ||
| Q3 24 | $2.66 | $1.63 | ||
| Q2 24 | $4.00 | $1.24 | ||
| Q1 24 | $2.70 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $2.4B |
| 总资产 | $29.4B | $4.9B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBEXPD
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.4B |
总债务BIIBEXPD
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBEXPD
| Q4 25 | $18.3B | $2.4B | ||
| Q3 25 | $18.2B | $2.3B | ||
| Q2 25 | $17.6B | $2.2B | ||
| Q1 25 | $17.0B | $2.3B | ||
| Q4 24 | $16.7B | $2.2B | ||
| Q3 24 | $16.4B | $2.4B | ||
| Q2 24 | $15.9B | $2.2B | ||
| Q1 24 | $15.2B | $2.2B |
总资产BIIBEXPD
| Q4 25 | $29.4B | $4.9B | ||
| Q3 25 | $29.2B | $4.8B | ||
| Q2 25 | $28.3B | $4.8B | ||
| Q1 25 | $28.0B | $4.8B | ||
| Q4 24 | $28.0B | $4.8B | ||
| Q3 24 | $28.3B | $5.2B | ||
| Q2 24 | $26.8B | $4.8B | ||
| Q1 24 | $26.6B | $4.5B |
负债/权益比BIIBEXPD
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $283.3M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $270.3M |
| 自由现金流率自由现金流/营收 | 20.5% | 9.5% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $953.4M |
8季度趋势，按日历期对齐
经营现金流BIIBEXPD
| Q4 25 | $511.9M | $283.3M | ||
| Q3 25 | $1.3B | $201.4M | ||
| Q2 25 | $160.9M | $179.2M | ||
| Q1 25 | $259.3M | $342.6M | ||
| Q4 24 | $760.9M | $249.7M | ||
| Q3 24 | $935.6M | $90.0M | ||
| Q2 24 | $625.8M | $126.8M | ||
| Q1 24 | $553.2M | $256.9M |
自由现金流BIIBEXPD
| Q4 25 | $468.0M | $270.3M | ||
| Q3 25 | $1.2B | $190.3M | ||
| Q2 25 | $134.3M | $163.3M | ||
| Q1 25 | $222.2M | $329.5M | ||
| Q4 24 | $721.6M | $239.7M | ||
| Q3 24 | $900.6M | $77.7M | ||
| Q2 24 | $592.3M | $118.8M | ||
| Q1 24 | $507.3M | $246.7M |
自由现金流率BIIBEXPD
| Q4 25 | 20.5% | 9.5% | ||
| Q3 25 | 48.4% | 6.6% | ||
| Q2 25 | 5.1% | 6.2% | ||
| Q1 25 | 9.1% | 12.4% | ||
| Q4 24 | 29.4% | 8.1% | ||
| Q3 24 | 36.5% | 2.6% | ||
| Q2 24 | 24.0% | 4.9% | ||
| Q1 24 | 22.1% | 11.2% |
资本支出强度BIIBEXPD
| Q4 25 | 1.9% | 0.5% | ||
| Q3 25 | 1.8% | 0.4% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 1.5% | 0.5% | ||
| Q4 24 | 1.6% | 0.3% | ||
| Q3 24 | 1.4% | 0.4% | ||
| Q2 24 | 1.4% | 0.3% | ||
| Q1 24 | 2.0% | 0.5% |
现金转化率BIIBEXPD
| Q4 25 | — | 1.41× | ||
| Q3 25 | 2.73× | 0.91× | ||
| Q2 25 | 0.25× | 0.98× | ||
| Q1 25 | 1.08× | 1.68× | ||
| Q4 24 | 2.85× | 1.06× | ||
| Q3 24 | 2.41× | 0.39× | ||
| Q2 24 | 1.07× | 0.72× | ||
| Q1 24 | 1.41× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
EXPD
| Customs Brokerage And Other Services | $1.1B | 40% |
| Airfreight Services | $1.1B | 39% |
| Ocean Freight And Ocean Services | $611.4M | 21% |
